Skye Bioscience, Inc. current report, 11 August 2016

Business Context and Reporting Period

This Form 8-K is filed by Nemus Bioscience, Inc. (not Skye Bioscience, Inc.) on August 11, 2016, reporting events that occurred on August 3, 2016. The filing addresses the resolution of legal disputes involving the Company and its former Chief Executive Officer, John B. Hollister.

Key Financial Metrics

The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on legal proceedings and does not contain financial statement data.

Material Changes

  • Legal Resolution: On August 3, 2016, John B. Hollister dismissed his complaint against Nemus Bioscience, Inc. and Executive Chairman Cosmas N. Lykos.
  • Counterclaim Dismissal: The Company and Mr. Lykos simultaneously dismissed their counterclaims against Hollister, which included allegations of defamation, false light, unfair competition, breach of contract, breach of fiduciary duty, and fraud.
  • Settlement Terms: A Settlement and Release of Claims Agreement was signed. Neither the Company nor Mr. Lykos made any payment to Hollister to resolve the lawsuit.
  • Executive Admission: Hollister issued a letter stating he regrets initiating the litigation and acknowledges that neither the Company nor Mr. Lykos engaged in wrongful conduct.
  • Court Order: The Orange County Superior Court entered an order dismissing the entire action with prejudice effective August 3, 2016.

Guidance, Outlook, and Risks

The filing does not contain financial guidance, future outlook, or management commentary regarding business operations. The primary risk addressed is the conclusion of the litigation, which the Company previously characterized as "grossly inaccurate" and "entirely without merit." The dismissal with prejudice eliminates the legal contingency associated with this specific dispute.

Investor Verification Checklist

  • Verify the company name discrepancy: The filing is for Nemus Bioscience, Inc., not Skye Bioscience, Inc.
  • Confirm the dismissal of the lawsuit with prejudice via Orange County Superior Court records.
  • Review Exhibit 99.1 (Settlement and Release of Claims) for any non-monetary obligations or future restrictions.
  • Check subsequent filings for any impact of the former CEO's termination (August 24, 2015) on current operations.